Privia Health is executing a provider-network expansion strategy that has accelerated revenue growth to 21.4% YoY in 2026Q2, yet gross margins remain structurally thin at 1.9%, underscoring the pass-through nature of value-based care economics.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $0.21+132.1% vs $0.09 | $657M+7.6% vs $611M |
Q3 2026 Aug 6, 2026 | $0.07+3.9% vs $0.07 | $633M+5.9% vs $597M |
Q2 2026 May 7, 2026 | $0.02-75.0% vs $0.08 | $604M+7.6% vs $561M |
Q1 2026 Feb 26, 2026 | $0.07+75.0% vs $0.04 | $541M+4.8% vs $516M |
Privia Health Group NASDAQ: PRVA raised its 2026 financial outlook after reporting growth in providers, patient attribution and adjusted earnings through the first nine months of the year. The company also announced a $36 million acquisition that will expand its Medicare value-based care footprint in 2027.
Privia Health Group, Inc. (PRVA) Q3 2026 Earnings Call Transcript
The headline numbers for Privia Health (PRVA) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Privia Health (PRVA) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.05 per share a year ago.
Benchmark PRVA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Privia Health Group, Inc. (PRVA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $24.42 | $3.08B | 93.28 | 22.26% | 1.43% | 4.2% | — | |
| $29.41 | $1.75B | -4.71 | 48.03% | -264.76% | -34.63% | — | |
| $69.74 | $34.45B | 23.59 | 19.44% | 0.75% | 6.76% | — | |
| $7.34 | $1.52B | 52.92 | 46.06% | 0.59% | 12.46% | — | |
| $30.65 | $7.95B | 12.41 | 27.5% | 4.9% | 49.39% | — | |
| $32.51 | $6.08B | 43.70 | 13.05% | 21.12% | 14.81% | — |
Privia Health Group, Inc. (PRVA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Privia Health Group, Inc. (PRVA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 7, 2026·SEC
May 22, 2026·SEC
Get notified when PRVA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Privia Health Group, Inc. (PRVA) stock FAQ — growth, dividends, profitability & financials explained
Privia Health Group, Inc. (PRVA) reported $2.43B in revenue over the trailing twelve months. Revenue was $2.12B in fiscal year 2025. That is 223% more than the $657.6M of fiscal year 2018.
Privia Health Group, Inc. (PRVA) grew revenue by 19.2% over the trailing twelve months, compared with the twelve months before.
Yes. Privia Health Group, Inc. (PRVA) earned $34.8M in net income over the trailing twelve months (a 1.4% net margin).
Privia Health Group, Inc. (PRVA) had a return on equity (ROE) of 4.2% over the trailing twelve months. That is below the market's typical 10-15%.
Privia Health Group, Inc. (PRVA) generated $108.0M in free cash flow over the trailing twelve months.
